New Insights into RSK Activation and Hematopoietic Cancer  by Cuadrado, Ana & Nebreda, Angel R.
Cancer Cell
PreviewsNew Insights into RSK Activation  
and Hematopoietic Cancer
Ana Cuadrado1 and Angel R. Nebreda1,*
1CNIO (Spanish National Cancer Center), Melchor Fernández Almagro, 3, E-28029 Madrid, Spain
*Correspondence: anebreda@cnio.es
DOI 10.1016/j.ccr.2007.08.017
The tyrosine kinase receptor FGFR3 is thought to play a role in hematopoietic malignancies. A new 
study in this issue of Cancer Cell identifies the serine/threonine kinase RSK2 as a key substrate of 
FGFR3 in human t(4;14)-positive multiple myeloma (MM) cells. Constitutively active FGFR3 directly 
phosphorylates RSK2 on Tyr529, which primes RSK2 for activation by the kinases ERK1 and ERK2 
(ERK1/2). In turn, RSK2 activity plays an important role in the survival of FGFR3-expressing MM cells.The elucidation of signal transduc-
tion mechanisms that underlie tumor 
initiation and progression should help 
to improve diagnosis as well as to 
identify potential therapeutic targets 
for rational cancer treatment. MM is a 
common hematological malignancy in 
elderly patients that affects terminally 
differentiated plasma B cells. Molecu-
lar and cytogenetic data indicate that 
translocations involving 14q32 into 
the immunoglobulin heavy (IgH) chain 
switch region are frequent in human 
MM cells. For example, about 15% 
of MM patients have the t(4;14) trans-
location that involves FGFR3, one 
of the four tyrosine kinase receptors 
that engage fibroblast growth factor 
(Chesi et al., 1997). In some cases, the 
translocated FGFR3 gene contains 
the activating mutation K650E and is 
referred to as FGFR3 TDII. Dysregu-
lated FGFR3 is also associated with 
other hematological malignancies 
such as peripheral T cell lymphomas, 
which express the constitutively active 
TEL-FGFR3 fusion formed by the tran-
scription factor TEL and the kinase 
domain of FGFR3. Studies with cell 
lines and murine models support a 
role for FGFR3 in hematopoietic cell 
transformation.
Characterization of the FGFR3-acti-
vated signaling pathways in hemato-
poietic malignancies is important to 
understand the pathogenesis of MM 
and to gain insights into potential 
therapeutic strategies. Interestingly, 
activating FGFR3 mutations do not 
occur in human MM cells harboring 
activating mutations of the GTPases K-RAS or N-RAS, suggesting that 
FGFR3 and RAS could contribute to 
MM progression via the same or sim-
ilar signaling pathways. Accordingly, 
leukemogenic FGFR3 TDII and TEL-
FGFR3 variants have been shown to 
activate the ERK1/2 kinase cascade, 
which is also one of the effectors of 
RAS whose dysregulation has been 
associated with cell transformation 
and cancer.
In this issue of Cancer Cell, Kang 
et al. (2007) report that the ERK1/2-
activated 90 kDa ribosomal S6 kinase 
RSK2 is a key mediator of FGFR3 sig-
naling in hematopoietic transforma-
tion. The RSK family includes four ser-
ine/threonine protein kinases that play 
important roles in many processes, 
including cell survival and prolifera-
tion (Hauge and Frodin, 2006). All 
RSK family members have similar 
overall structure, with two nonidenti-
cal, tandem kinase domains (referred 
to as NTK and CTK) separated by a 
linker region. RSK activation requires 
the sequential phosphorylation of 
four residues by ERK1/2, by RSK 
itself, and by PDK1, a process that is 
initiated by the binding of ERK1/2 to a 
docking site located at the C-terminal 
end of the RSK protein (Figure 1).
In an effort to understand FGFR3 
signaling in hematopoietic malignan-
cies, Kang et al. performed a mass 
spectrometry-based phospho-pro-
teomic analysis in murine Ba/F3 
cells expressing leukemogenic 
TEL-FGFR3, which bypasses the 
requirement of IL-3 for proliferation. 
In this study, constitutively active Cancer Cell 12, STEL-FGFR3 was found to induce the 
phosphorylation of RSK2 on Tyr488 
and Tyr529. Further characteriza-
tion showed that phosphorylation of 
Tyr529, but not of Tyr488, was impor-
tant for RSK2 activation downstream 
of FGFR3. Moreover, recombinant 
FGFR3 was able to directly phos-
phorylate Tyr529 of RSK2 in vitro.
How does Tyr529 phosphorylation 
contribute to RSK2 activation? The 
results by Kang et al. indicate that 
Tyr529 phosphorylation enhances 
the interaction between RSK2 and 
ERK1/2, which in turn should facilitate 
the activation of RSK2. This conclu-
sion is unexpected because there was 
no previous evidence that posttrans-
lational modification of RSK2 is nec-
essary for the binding of ERK1/2 to 
its C-terminal docking site, although 
RSK autophosphorylation at Ser737 is 
known to contribute to its inactivation 
by decreasing its affinity for ERK1/2. 
In agreement with this, the inactive 
(unphosphorylated) forms of ERK1/2 
and RSK can be coimmunoprecipi-
tated from cells that have not been 
stimulated with mitogens (Gavin and 
Nebreda, 1999; Roux et al., 2003). 
The structural basis for how Tyr529 
phosphorylation can boost binding of 
ERK1/2 to the docking site of RSK2 
located about 200 amino acids away 
remains to be elucidated.
Whether tyrosine phosphorylation 
of RSK2 is a specific requirement of 
FGFR3 signaling in hematopoietic 
cells or it might represent a more gen-
eral mechanism for RSK2 activation 
is not clear yet. Intriguingly, Kang et eptember 2007 ©2007 Elsevier Inc. 187
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Previewsfigure 1. Molecular Mechanisms of fGfR3-Induced RSK2 Activation
(A) Tyrosine kinase receptors, such as FGFR3, trigger the activation of ERK1/2 by a pathway 
that is initiated by oligomerization and autophosphorylation of the receptor upon ligand binding. 
This is followed by recruitment of the GRB2-SOS complex and the sequential activation of RAS 
and the kinases RAF and MEK1 and MEK2 (MEK1/2), which directly phosphorylate and activate 
ERK1/2. In turn, RSK2 activation requires the binding of ERK1/2 to a docking site sequence lo-
cated at its C terminus. ERK1/2 phosphorylates at least two residues, Ser369 in the linker region 
and Thr577 in the activation loop of CTK (1). Phosphorylation of Thr577 activates CTK, which 
then phosphorylates Ser386 in the linker region and generates a docking site for PDK1 (2). Finally, 
PDK1 phosphorylates Ser227 in the activation loop of NTK (3), resulting in fully active RSK2 that 
phosphorylates its downstream targets via NTK.
(B) In hematopoietic cancer cells, constitutively active TEL-FGFR3 and FGFR3 TDII (see text) 
can induce RSK2 activation by a two-step mechanism. FGFR3 phosphorylates RSK2 at Tyr529 
(a), facilitating the binding of ERK1/2 to the C-terminal docking site of RSK2. In addition, FGFR3 
triggers the classical ERK1/2 activation pathway that leads to the phosphorylation and activation 
of RSK2 (b), as explained above. ERK5, another member of the mitogen-activated kinase family, 
might play a role in FGFR3-induced RSK2 activation during leukemogenesis. Small-molecule 
RSK inhibitors are indicated.al. mention in passing that RSK2 can 
be phosphorylated on Tyr529 upon 
EGF stimulation of 293T cells, sug-
gesting that other tyrosine kinases, in 
addition to FGFR3, could contribute 
to RSK activation via direct tyrosine 
phosphorylation. It should be noted 
that Tyr529 is conserved in the four 
mammalian RSK family members as 
well as in Xenopus and Drosophila 
RSK proteins.
At the functional level, Kang et al. 
addressed the role of RSK2 in hema-
topoietic transformation. They found 
that FGFR3-induced activation of 
RSK2 was required for the survival of 
both murine Ba/F3 cells expressing 
leukemogenic FGFR3 mutants and 
human t(4;14)-positive MM cells that 
express FGFR3. Curiously, RSK1 did 
not appear to significantly contrib-188 Cancer Cell 12, September 2007 ©2ute to FGFR3-induced cell survival, 
suggesting a specific requirement 
for RSK2 but not RSK1 in mediating 
oncogenic FGFR3 signaling. Of note, 
it has been recently shown that ecto-
pic activation of the MEK5/ERK5 path-
way in HEK293 cells activates RSK2 
but not RSK1 (Cude et al., 2007), and 
ERK5 has also been implicated in the 
regulation of MM cell survival (Carva-
jal-Vergara et al., 2005). Whether the 
ERK5 pathway might be involved in the 
FGFR3-induced activation of RSK2 in 
MM cells deserves further study. It 
also remains to be established what 
targets of RSK2 account for its contri-
bution to MM cell survival.
The requirement for RSK2 in sur-
vival of human t(4;14)-positive MM 
cells is noteworthy in light of the 
recent development of very specific 007 Elsevier Inc.RSK inhibitors (Cohen et al., 2007; 
Sapkota et al., 2007). Fmk is a RSK 
inhibitor whose specificity is based 
on the presence of a cysteine resi-
due and a threonine residue at par-
ticular positions in the ATP-binding 
site of CTK, which are only present 
in the human kinases RSK1, RSK2, 
and RSK4. Kang et al. found that 
treatment with fmk led to increased 
apoptosis in several human t(4;14)-
positive MM cell lines as well as 
in primary FGFR3-expressing MM 
cells (CD138+) from a t(4;14)-positive 
patient. Importantly, the survival of 
CD138− cells from the same patient 
or CD138+ cells from a t(4;14)-nega-
tive patient was not affected by fmk. 
These results are in agreement with 
a previous report showing that RSK 
inhibition impaired the proliferation of 
breast cancer cells, while having little 
effect on nontumoral cells (Smith et 
al., 2005). Moreover, the triple knock-
out of RSK1, RSK2, and RSK3 does 
not appear to affect mouse viability 
(Dumont et al., 2005), further sug-
gesting that specific RSK inhibitors 
might not have serious side effects in 
organism homeostasis. Future work 
should extend these studies and 
address the therapeutic window of 
small-molecule RSK inhibitors.
Finally, Kang et al. report that fmk can 
also induce apoptosis in the t(4;14)-
negative MM cell line RPMI8226, which 
lacks FGFR3 expression but contains 
active RSK2, probably induced by the 
expression of oncogenic RAS. This 
result suggests a wider range of pos-
sible therapeutic applications for RSK 
inhibitors in cancer treatment beyond 
FGFR3-positive MM.
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BCL6 is a proto-oncogene encod-
ing a POZ/Zinc finger sequence-
specific transcriptional repressor, 
which is distinctively expressed in 
GC B cells. In the GC, BCL6 exerts 
antiapoptotic effects and favors 
sustained proliferation of B cells by 
modulating the transcription of genes 
involved in cell cycle regulation, pro-
liferation, activation, CSR, and dif-
ferentiation (Shaffer et al., 2000). The 
expression of BCL6 in the GC lym-
phocytes is tightly regulated at both 
the transcriptional and the protein 
levels. BCL6 gene is negatively self-
regulated by binding of BCL6 to spe-
cific binding sequences located in its 
first exon (Wang et al., 2002). Activa-
tion of STAT5 may either upregulate 
or suppress BCL6 expression, and 
p53 may increase BCL6 expression 
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